- Home
- U vs INCY Comparison
U vs INCY Comparison
Compare U & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- U
- INCY
- Stock Information
- Founded
- U 2004
- INCY 1991
- Country
- U United States
- INCY United States
- Employees
- U N/A
- INCY N/A
- Industry
- U Retail: Computer Software & Peripheral Equipment
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- U Technology
- INCY Health Care
- Exchange
- U Nasdaq
- INCY Nasdaq
- Market Cap
- U 13.4B
- INCY 13.0B
- IPO Year
- U 2020
- INCY 1993
- Fundamental
- Price
- U $45.58
- INCY $86.02
- Analyst Decision
- U Buy
- INCY Buy
- Analyst Count
- U 16
- INCY 20
- Target Price
- U $31.60
- INCY $80.31
- AVG Volume (30 Days)
- U 12.0M
- INCY 1.8M
- Earning Date
- U 11-06-2025
- INCY 10-28-2025
- Dividend Yield
- U N/A
- INCY N/A
- EPS Growth
- U N/A
- INCY 900.04
- EPS
- U N/A
- INCY 4.37
- Revenue
- U $1,779,560,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- U $1.36
- INCY $16.26
- Revenue Next Year
- U $9.41
- INCY $11.07
- P/E Ratio
- U N/A
- INCY $19.83
- Revenue Growth
- U N/A
- INCY 18.87
- 52 Week Low
- U $15.33
- INCY $53.56
- 52 Week High
- U $44.22
- INCY $87.99
- Technical
- Relative Strength Index (RSI)
- U 77.42
- INCY 62.27
- Support Level
- U $38.85
- INCY $85.06
- Resistance Level
- U $40.67
- INCY $87.99
- Average True Range (ATR)
- U 2.04
- INCY 1.63
- MACD
- U 0.35
- INCY -0.40
- Stochastic Oscillator
- U 99.64
- INCY 56.99
About U Unity Software Inc.
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. The products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.